TNFSF11 and neoplasm: Denosumab, a humanized monoclonal antibody to RANKL, which inhibits bone resorption by osteoclasts, has shown its efficacy in clinical trials of giant cell tumour of bone (Heymann, 2012) and significantly reduced or eliminated RANK positive tumour giant cells (Branstetter et al., 2012).